234 related articles for article (PubMed ID: 35875870)
21. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.
Wang H; Tsao ST; Gu M; Fu C; He F; Li X; Zhang M; Li N; Hu HM
J Transl Med; 2022 Dec; 20(1):608. PubMed ID: 36536403
[TBL] [Abstract][Full Text] [Related]
22. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21.
Ptáčková P; Musil J; Štach M; Lesný P; Němečková Š; Král V; Fábry M; Otáhal P
Cytotherapy; 2018 Apr; 20(4):507-520. PubMed ID: 29475789
[TBL] [Abstract][Full Text] [Related]
23. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
[TBL] [Abstract][Full Text] [Related]
24. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
Sun W; Jiang Z; Jiang W; Yang R
Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
[TBL] [Abstract][Full Text] [Related]
25. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
26. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
27. The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies.
Guo Z; Zhang Y; Fu M; Zhao L; Wang Z; Xu Z; Zhu H; Lan X; Shen G; He Y; Lei P
Front Immunol; 2021; 12():652924. PubMed ID: 33854512
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
29. Strategies for manufacturing cell therapy products aligned with patient needs.
Guha P; Katz SC
Methods Cell Biol; 2022; 167():203-226. PubMed ID: 35152997
[TBL] [Abstract][Full Text] [Related]
30. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.
Singh AP; Zheng X; Lin-Schmidt X; Chen W; Carpenter TJ; Zong A; Wang W; Heald DL
MAbs; 2020; 12(1):1688616. PubMed ID: 31852337
[TBL] [Abstract][Full Text] [Related]
31. Release Assays and Potency Assays for CAR T-Cell Interventions.
Dias J; Cadiñanos-Garai A; Roddie C
Adv Exp Med Biol; 2023; 1420():117-137. PubMed ID: 37258787
[TBL] [Abstract][Full Text] [Related]
32. Overcoming Challenges in Process Development of Cellular Therapies.
Highfill SL; Stroncek DF
Curr Hematol Malig Rep; 2019 Aug; 14(4):269-277. PubMed ID: 31278568
[TBL] [Abstract][Full Text] [Related]
33. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
34. Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype.
Pampusch MS; Skinner PJ
J Vis Exp; 2020 Mar; (157):. PubMed ID: 32250358
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
36. [Chimeric antigen receptors (CARs): universal tools in adoptive cell therapy].
Holzinger A; Abken H
Internist (Berl); 2021 Jun; 62(6):583-588. PubMed ID: 33928413
[TBL] [Abstract][Full Text] [Related]
37. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
38. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
39. [CAR T cells as drugs for novel therapies (advanced therapy medicinal products)].
Köhl U; Abken H
Internist (Berl); 2021 Apr; 62(4):449-457. PubMed ID: 33590292
[TBL] [Abstract][Full Text] [Related]
40. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
Ruppel KE; Fricke S; Köhl U; Schmiedel D
Front Immunol; 2022; 13():822298. PubMed ID: 35371071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
